Have a feature idea you'd love to see implemented?
Let us know!
ALLO Allogene Therapeutics Inc
Price (delayed)
$2.11
Market cap
$442.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.59
Enterprise value
$466.01M
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
Highlights
The EPS has grown by 31% YoY and by 3% from the previous quarter
The net income has increased by 17% YoY
The gross profit has dropped by 165% year-on-year
ALLO's revenue has dropped by 165% year-on-year
Key stats
What are the main financial stats of ALLO
Market
Valuations
Earnings
Shares outstanding
209.67M
Market cap
$442.41M
Enterprise value
$466.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.95
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
-$22,000
EBIT
-$286.81M
EBITDA
-$272.93M
Free cash flow
-$217.93M
Per share
Balance sheet
Liquidity
EPS
-$1.59
Free cash flow per share
-$1.04
Book value per share
$2.22
Revenue per share
$0
TBVPS
$2.82
Total assets
$589.12M
Total liabilities
$125.37M
Debt
$85.14M
Equity
$463.75M
Working capital
$271.84M
Debt to equity
0.18
Current ratio
9.35
Quick ratio
9.27
Net debt/EBITDA
-0.09
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.6%
Return on equity
-58.8%
Return on invested capital
-54.5%
Return on capital employed
-51.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLO stock price
How has the Allogene Therapeutics stock price performed over time
Intraday
2.93%
1 week
-14.23%
1 month
-24.64%
1 year
-25.18%
YTD
-34.27%
QTD
-24.64%
Financial performance
How have Allogene Therapeutics's revenue and profit performed over time
Revenue
-$22,000
Gross profit
-$22,000
Operating income
-$297.88M
Net income
-$286.91M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 165% year-on-year
ALLO's revenue has dropped by 165% year-on-year
The net income has increased by 17% YoY
ALLO's operating income is up by 12% year-on-year but it is down by 3% since the previous quarter
Growth
What is Allogene Therapeutics's growth rate over time
Valuation
What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
0.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 31% YoY and by 3% from the previous quarter
ALLO's price to book (P/B) is 63% less than its 5-year quarterly average of 2.5 and 23% less than its last 4 quarters average of 1.2
Allogene Therapeutics's equity has decreased by 20% YoY and by 10% QoQ
ALLO's revenue has dropped by 165% year-on-year
Efficiency
How efficient is Allogene Therapeutics business performance
The return on equity has declined by 8% since the previous quarter and by 5% year-on-year
The return on assets has declined by 7% since the previous quarter and by 3.3% year-on-year
ALLO's return on invested capital is down by 6% since the previous quarter and by 6% year-on-year
Dividends
What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLO.
Financial health
How did Allogene Therapeutics financials performed over time
ALLO's quick ratio is down by 27% year-on-year and by 24% since the previous quarter
ALLO's current ratio is down by 26% YoY and by 24% from the previous quarter
Allogene Therapeutics's debt is 82% less than its equity
The company's debt to equity rose by 20% YoY
Allogene Therapeutics's equity has decreased by 20% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.